Interpace Biosciences, Inc. (IDXG)

Interpace Biosciences, Inc. (IDXG) Healthcare & Pipeline Overview

Interpace Biosciences, Inc. is a U.S.-based healthcare company delivering specialized molecular diagnostic tests and bioinformatics services for cancer risk assessment. Leveraging platforms like PathFinderTG, it provides critical insights for pancreatic, thyroid, and lung cancer detection, positioning itself within the evolving precision medicine landscape.

What Is the Investment Thesis for IDXG?

Interpace Biosciences, Inc. (IDXG) presents an investment profile centered on its specialized molecular diagnostic tests for cancer risk assessment, operating within the high-growth healthcare sector. The company's portfolio, including PancraGEN for pancreatic cancer and ThyGeNEXT/ThyraMIR for thyroid nodules, addresses critical diagnostic needs with proprietary technology. A notable financial highlight is its robust Profit Margin of 65.2% and Gross Margin of 62.5%, indicating strong operational efficiency relative to its revenue. With a P/E ratio of 1.7, the company demonstrates profitability. Growth catalysts include the increasing adoption of precision medicine, expansion of its diagnostic test offerings, and leveraging its bioinformatics capabilities for broader applications. The company's services to pharmaceutical and biotech industries also represent a stable revenue stream. However, its small market capitalization of $45.71M and OTC 'Other' tier classification introduce considerations regarding liquidity and disclosure, which potential investors must factor into their due diligence. The company's beta of 0.61 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

IDXG Key Highlights

• Interpace Biosciences maintains a strong Profit Margin of 65.2%, indicating high profitability from its diagnostic services.
• The company demonstrates robust operational efficiency with a Gross Margin of 62.5%, showcasing effective cost management relative to its revenue.
• With a P/E ratio of 1.7, Interpace Biosciences is profitable, suggesting its earnings are substantial relative to its market valuation.
• The company's market capitalization stands at $0.01 billion, reflecting its status as a micro-cap entity within the diagnostics sector.
• Interpace Biosciences exhibits a Beta of 0.61, suggesting its stock price has historically been less volatile than the overall market.

Who Are IDXG's Competitors?

IDXG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IDXG's Key Strengths?

• Proprietary and specialized molecular diagnostic tests for various cancers (pancreatic, thyroid, lung).
• Strong financial performance indicated by high Profit Margin (65.2%) and Gross Margin (62.5%).
• Diverse service offerings including pharmacogenomics and customized services for the biotech industry.
• Established customer base serving physicians, hospitals, and clinics across the U.S.

What Are IDXG's Weaknesses?

• Small market capitalization ($0.01B) potentially limiting access to capital for large-scale expansion.
• Reliance on a relatively narrow range of specialized diagnostic tests.
• Operating on the OTC market, which can entail lower liquidity and less visibility.
• Disclosure status is 'Unknown' on the OTC market, potentially hindering investor confidence.

What Could Drive IDXG Stock Higher?

• Increased adoption rates for PancraGEN and ThyGeNEXT tests as awareness grows among healthcare providers regarding their diagnostic utility in cancer risk assessment.
• Expansion of services to pharmaceutical and biotech industries, including pharmacogenomics testing and biorepository services, driving diversified revenue streams.
• Potential for new product development or enhancements to existing diagnostic platforms, leading to broader market applications or improved diagnostic accuracy.
• Favorable shifts in healthcare reimbursement policies for molecular diagnostics, potentially improving access and financial viability for Interpace Biosciences' tests.
• Strategic partnerships or collaborations with larger healthcare organizations or research institutions to expand market reach and clinical validation efforts.

What Are the Key Risks for IDXG?

• Financial-distress signal — its Altman Z-Score of -4.56 sits in the distress zone (elevated bankruptcy risk).
• Intense competition within the molecular diagnostics market from larger, well-funded companies could limit market share and pricing power for Interpace Biosciences.
• Regulatory changes or stricter oversight in the diagnostics industry could increase compliance costs and impact product development timelines.
• Dependence on a limited number of proprietary diagnostic tests means that any issues with these products, such as clinical efficacy or market acceptance, could significantly impact revenue.
• The 'Unknown' disclosure status on the OTC market poses a risk to investor confidence and makes it challenging to access timely, comprehensive financial information.
• Reimbursement challenges or unfavorable changes in insurance coverage for molecular diagnostic tests could reduce demand and profitability for the company's services.

What Are the Growth Opportunities for IDXG?

• **Expansion of Pancreatic Cancer Diagnostics Market Penetration:** The market for pancreatic cancer diagnostics is growing due to increasing incidence and the critical need for early detection. Interpace Biosciences' PancraGEN and PanDNA tests offer advanced genomic insights for pancreatic cyst and lesion risk assessment. Expanding sales and marketing efforts to a wider network of gastroenterologists, oncologists, and surgeons across the United States could significantly increase test volume. This opportunity leverages the existing proprietary PathFinderTG platform and addresses an unmet need for more precise risk stratification, potentially capturing a larger share of a market driven by an aging population and improved screening protocols over the next 3-5 years.
• **Increased Adoption of Thyroid Nodule Malignancy Assessment:** Thyroid cancer incidence has been rising, leading to a greater demand for accurate diagnostic tools for thyroid nodules. Interpace Biosciences' ThyGeNEXT and ThyraMIR tests provide complementary genomic and microRNA analyses to identify malignant nodules, reducing unnecessary surgeries. By demonstrating superior diagnostic accuracy and clinical utility through further studies and physician education, the company can drive broader adoption among endocrinologists and surgeons. This growth avenue capitalizes on a substantial patient population undergoing thyroid nodule evaluations, with potential for increased test utilization over the next 2-4 years as clinical guidelines evolve.
• **Leveraging Pharmacogenomics and Customized Services:** The pharmacogenomics market is expanding rapidly as personalized medicine gains traction, offering significant growth for companies providing related services. Interpace Biosciences already offers pharmacogenomics testing, genotyping, and biorepository services to pharmaceutical and biotech industries. By actively marketing these customized services, including contract research and development support, the company can attract new industry partners. This strategy diversifies revenue streams beyond direct patient diagnostics and taps into the robust R&D spending of the biopharmaceutical sector, with opportunities for long-term partnerships and recurring revenue over the next 5 years.
• **Development and Commercialization of New Diagnostic Solutions:** Continuous innovation in molecular diagnostics is crucial for sustained growth. Interpace Biosciences has a foundation in genomic and microRNA analysis, which can be extended to develop new diagnostic tests for other cancer types or disease areas. Investing in R&D to identify novel biomarkers and create new proprietary assays, potentially through collaborations with academic institutions or biotech firms, could open entirely new market segments. This forward-looking strategy positions the company for future market leadership and addresses evolving diagnostic needs, with new product launches potentially occurring within a 3-7 year timeframe.
• **Geographic Expansion and Strategic Partnerships:** While primarily serving the United States, there may be opportunities for Interpace Biosciences to explore strategic partnerships or licensing agreements to expand its diagnostic test offerings into international markets. The global demand for advanced cancer diagnostics is universal, and collaborating with established diagnostic providers in key regions could facilitate market entry without significant capital expenditure. Additionally, forming alliances with large healthcare systems or integrated delivery networks within the U.S. could streamline access to a broader patient base. This approach could unlock new revenue streams and enhance brand recognition over a 4-6 year horizon.

What Opportunities Does IDXG Have?

• Growing demand for precision medicine and early cancer detection, driving adoption of molecular diagnostics.
• Potential for expanding the application of existing diagnostic platforms to other disease areas.
• Increased partnerships with pharmaceutical and biotech companies for pharmacogenomics and research services.
• Geographic expansion or strategic alliances to reach broader patient populations.

What Threats Does IDXG Face?

• Intense competition from larger, more diversified diagnostic companies with greater resources.
• Rapid technological advancements by competitors could render existing tests less competitive.
• Changes in healthcare reimbursement policies or regulatory landscape affecting diagnostic test coverage.
• Potential for adverse clinical study results or limited market acceptance of new diagnostic offerings.

What Are IDXG's Competitive Advantages?

• Proprietary diagnostic tests like PancraGEN, ThyGeNEXT, ThyraMIR, and RespriDx, which are based on unique genomic and microRNA assays.
• Specialized bioinformatics capabilities and the PathFinderTG platform, offering advanced analysis for complex diagnostic challenges.
• Clinical validation and established relationships with healthcare providers in niche cancer diagnostic areas.
• Expertise in pharmacogenomics and customized services, creating a specialized offering for the pharmaceutical and biotech industries.
• Regulatory approvals and intellectual property surrounding its diagnostic methodologies.

What Does IDXG Do?

Interpace Biosciences, Inc., incorporated in 1986 and headquartered in Parsippany, New Jersey, has evolved into a key provider of molecular diagnostic tests, bioinformatics, and pathology services dedicated to evaluating cancer risk across the United States. Initially known as Interpace Diagnostics Group, Inc., the company rebranded in November 2019 to better reflect its focus on advanced biosciences. Its core offerings include PancraGEN, a comprehensive genomic test for pancreatic cysts and pancreaticobiliary solid lesions, which utilizes the proprietary PathFinderTG platform to assist physicians in assessing cancer risk. Complementing this is PanDNA, a molecular-only version of PancraGEN providing a focused snapshot of limited factors. For thyroid cancer diagnostics, Interpace Biosciences offers ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules, and ThyraMIR, which assesses malignancy risk using a proprietary microRNA gene-expression assay. Additionally, RespriDx is a genomic test aiding physicians in differentiating metastatic or recurrent lung cancer. Beyond its direct diagnostic services, the company extends its expertise to the pharmaceutical and biotech industries, providing pharmacogenomics testing, genotyping, biorepository services, and various other customized solutions. Interpace Biosciences primarily serves a diverse client base comprising physicians, hospitals, and clinics, aiming to enhance diagnostic precision and patient care through its specialized molecular insights.

What Products and Services Does IDXG Offer?

• Provide molecular diagnostic tests for evaluating cancer risk, primarily in the United States.
• Offer PancraGEN, a genomic test for pancreatic cysts and pancreaticobiliary solid lesions using the PathFinderTG platform.
• Supply PanDNA, a molecular-only version of PancraGEN for focused risk assessment.
• Deliver ThyGeNEXT, an oncogenic mutation panel for identifying malignant thyroid nodules.
• Provide ThyraMIR, a microRNA gene-expression assay for assessing thyroid nodule malignancy risk.
• Offer RespriDx, a genomic test to differentiate metastatic or recurrent lung cancer.
• Conduct pharmacogenomics testing, genotyping, and biorepository services for pharmaceutical and biotech industries.
• Serve physicians, hospitals, and clinics with specialized diagnostic and pathology services.

How Does IDXG Make Money?

• Generate revenue through the sale and processing of proprietary molecular diagnostic tests to healthcare providers.
• Earn income by providing customized pharmacogenomics testing, genotyping, and biorepository services to pharmaceutical and biotech companies.
• Leverage proprietary platforms like PathFinderTG and specialized microRNA assays to offer unique diagnostic insights.
• Focus on high-value, specialized cancer diagnostics where precision and early detection are critical.
• Operate primarily on a fee-for-service model for diagnostic testing.

What Industry Does IDXG Operate In?

Interpace Biosciences operates within the Medical - Diagnostics & Research industry, a dynamic segment of the healthcare sector characterized by continuous innovation and increasing demand for precise, early disease detection. The broader market for molecular diagnostics is experiencing significant growth, driven by advancements in genomic sequencing, personalized medicine, and the rising global burden of chronic diseases, particularly cancer. Interpace Biosciences carves out a niche with its specialized molecular tests for pancreatic, thyroid, and lung cancers, areas where accurate and early diagnosis can significantly impact patient outcomes. The competitive landscape includes larger diagnostic companies and specialized biotech firms, all vying for market share through technological superiority, clinical validation, and market penetration. Interpace Biosciences' focus on proprietary genomic and microRNA assays positions it as a specialized player, aiming to differentiate through the efficacy and specificity of its diagnostic platforms like PathFinderTG.

Who Are IDXG's Key Customers?

• Physicians, including oncologists, gastroenterologists, endocrinologists, and pulmonologists.
• Hospitals and hospital systems seeking advanced diagnostic capabilities.
• Clinics and specialized medical practices.
• Pharmaceutical companies requiring pharmacogenomics and genotyping services.
• Biotechnology companies utilizing biorepository and customized research services.

Company Profile

Interpace Biosciences, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Parsippany, US. The company is led by CEO Thomas W. Burnell. IDXG has traded publicly since 1998.

How Interpace Biosciences, Inc. Is Valued

Interpace Biosciences, Inc. carries a market capitalization of $45.71M, placing it in the micro-cap category. Relative to its peer group, IDXG's quantitative score of 51/100 is below the peer average of 64/100.

ROE 215%Key Financial Metrics

Return on equity for Interpace Biosciences, Inc. stands at 215.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 70.8%, showing how much profit it generates from its asset base. IDXG trades at a trailing price-to-earnings ratio of 1.70, below the Healthcare sector average of ~23x. Its free cash flow yield is 9.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.51 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 63.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9Financial Health

Interpace Biosciences, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -4.56 places it in the distress zone, a signal of elevated financial risk.

IDXG Financials

IDXG Latest News

IDXG Analyst Consensus

IDXG MoonshotScore

Common Questions About IDXG (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources